Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Trial Profile

A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Non-small cell lung cancer; Small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2018 Planned End Date changed from 1 Nov 2019 to 1 Dec 2020.
    • 05 Nov 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2019.
    • 05 Nov 2018 Status changed from suspended to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top